| Literature DB >> 16696860 |
Derek E Dimcheff1, L Gwenn Volkert, Ying Li, Angelo L DeLucia, William P Lynch.
Abstract
BACKGROUND: Certain murine leukemia viruses (MLVs) are capable of inducing progressive spongiform motor neuron disease in susceptible mice upon infection of the central nervous system (CNS). The major CNS parenchymal target of these neurovirulent retroviruses (NVs) are the microglia, whose infection is largely coincident with neuropathological changes. Despite this close association, the role of microglial infection in disease induction is still unknown. In this paper, we investigate the interaction of the highly virulent MLV, FrCasE, with microglia ex vivo to evaluate whether infection induces specific changes that could account for neurodegeneration. Specifically, we compared microglia infected with FrCasE, a related non-neurovirulent virus (NN) F43/Fr57E, or mock-infected, both at a basic virological level, and at the level of cellular gene expression using quantitative real time RT-PCR (qRT-PCR) and Afffymetrix 430A mouse gene chips.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16696860 PMCID: PMC1475625 DOI: 10.1186/1742-4690-3-26
Source DB: PubMed Journal: Retrovirology ISSN: 1742-4690 Impact factor: 4.602
Figure 1Characterization of FrCasE-, Fr57E- or mock-infected primary microglia. Panel A shows the basic proviral structures of the viruses employed in this study. The env genes from the NV CasBrE (clone 15-1) and NN Friend virus clone Fr57 were introduced into the background of the Friend virus clone FB-29 to generate FrCasE and Fr57E/F43, respectively. These chimeric viruses differ only in their env genes. The two Fr57 env containing constructs (Fr57E and F43) differ by the restriction sites used for env introduction, however, no amino acid coding differences exists between the two clones. SD = splice donor; SA = splice acceptor. Panel B shows immunostaining of microglia isolated from mixed glial cultures to assess cell morphology, the extent of virus infection, and cell purity. The upper two panels show FrCasE-infected (left) and mock-infected (right) cells, stained with the CasBrE Env-specific monoclonal antibody 667. The lower panels show dual staining of Fr57E-infected microglia for Friend Env protein (left, red), and the macrophage/microglial marker Mac-1 (right). While virtually all the isolated cells were positive for virus infection and microglial markers, the level of cell surface staining varied considerably from very high (arrows) to very low (arrowheads) indicating significant cell surface expression heterogeneity. Importantly, no virus specific cell staining was observed in mock-infected controls using either antibodies to CasBrE or Friend Envs. Panel C shows Western blotting for Env (upper panel) and Gag (lower panel) on multiple FrCasE- (n = 3), Fr57E- (n = 4), and mock-infected (n = 3) microglial preparations. The right hand lane in each cell grouping shows immunoreactivity for mock-, Fr57E-, and FrCasE-infected 3T3 fibroblasts as a control. The far right hand grouping for FrCasE-infected samples shows immunoblotting results using the CasBrE Env specific monoclonal antibody 697. Note that the Env protein from microglia (Mg) is primarily a high molecular weight form for both FrCasE and Fr57E, whereas in 3T3 fibroblasts both high and low molecular weight species are observed. Note also that the Fr57 Env has a higher apparent molecular weight than the CasBrE Env protein consistent with known sequence and glycosylation differences. Pr65Gag is similar for Fr57E- and FrCasE-infected microglia; however, microglia expressed pr65 gag and glycoGag while 3T3 fibroblasts expressed pr65gag and gag-pol polyprotein. Panel D shows the virus expression levels generated from infected microglia and mixed glial cultures over a 24 hour period. No significant differences in virus production were noted between FrCasE (black bars) and Fr57E (gray bars) in either microglial or mixed glial cultures, however, the difference in virus production between microglia and mixed glia were highly significant with p values of <0.01 (FrCasE-infected microglia, n = 4; FrCasE-infected mixed glia, n = 6; Fr57E-infected microglia, n = 4; Fr57E-infected mixed glia, n = 5). No virus was detected from mock-infected microglia or mixed glia and thus the data were not shown.
Figure 2Taqman real-time RT-PCR analysis of ER stress genes in mock-, Fr57E-, and FrCasE-infected microglia. Panel A shows a gene expression comparison of FrCasE-, Fr57E- and mock-infected cultured microglia (Mg) for a subset of genes previously shown to be differentially expressed in the brains of FrCasE-infected mice compared to mock- and F43/Fr57E- infected controls [29]. Panel B shows a Western Blot for CHOP/GADD153 protein expression levels in equivalent samples from cultured microglia with mock, Fr57E and FrCasE virus infection, with and without 1 μM thapsigargin treatment for 24 hours in culture. For comparison purposes equivalent samples from mixed glial cultures (1°CNS) were assayed in parallel (right). No differences in CHOP expression were noted between mock-, Fr57E-, and FrCasE infected microglia or 1°CNS cultures, with or without thapsigargin treatment when evaluated in triplicate (not shown). Panel C shows Taqman real-time RT-PCR analysis on enriched microglial fractions taken from mock-, F43-, or FrCasE-infected brains of IRW mice 14 dpi. RT-PCR was performed on three biological replicates for each gene, and each replicate was amplified in three separate reactions and normalized to either GAPDH or ribosomal protein S29. Viral RNA was also assessed in these samples with primers and probes specific for the Friend FB-29 viral background common to FrCasE and Fr57E. F4/80 message levels were used to assess microglial enrichment, which was greater than 50 fold. Black bars = FrCasE-infected; Gray bars = Fr57E infected; white = mock infected.
Survey of Highly Expressed Genes1in Freshly Isolated Microglia ± MLV Infection
| L31, 10, S27a, L38, L41, L35, S23, L23, L35a, S28, L3, L7a, S3, L27a, S6, S4, S3a, S29, S18, S17, S16, S12, L5, L37a, L26, L13, L13a, L18, L24, S8, S14, L12, L29, L30, S20, S11, S24, S8, S19, L7, L21; Translation elongation factor 1α1, Laminin receptor. |
| Non-muscle beta actin, Actin-like gene, Vimentin, Alpha-tubulin, Thymosins β4 and β10, Fibronectin, Secreted phosphoprotein 1. |
| Metallothionen 1, Ferritin light chain, Ferritin heavy chain, Transferrin. |
| Heat shock proteins 8, 1; Calreticulin; Peroxiredoxins; Ubiquitins C, B, & A52; Cathepsins D, B, H, L, and Z. |
| Aldo-keto reductase, non-neuronal enolase, Aldolase, Lactate dehydrogenase, Phosphoglycerate kinase 1, Prosaposin, Lipoprotein lipase. |
| Translationally controlled tumor protein 1 |
| Granulin, TYRO Protein tryrosine kinase binding protein |
| CD9, CD14 (LPS receptor), CD53 (Ox 44), CD68 (Macrosialin), CD164, CD81, CD47, CD44, CD24, Toll-like Receptor 2, Galactose binding lectin, Interleukin-18, CSF-1 receptor, Macrophage expressed gene 1, Histocompatibility locus 2D, β2-microglobulin, C-type lectin, Tumor growth factor-beta greceptor, Lyphocyte cytosolic protein, Tumor necrosis factor-αlpha, Complement C1q, Chemokine ligand 6. Macrophage scavenger receptor, Fc Receptors for IgG and IgE, Lymphotaxin, Macrophage inflammatory protein-1αlpha, Macrophage inflammatory protein -1γamma, Macrophage migration inhibiting factor, LAMP-1, Lysozyme eosinophil-associated RNAse. |
| Apolipoprotein E, Amyloid beta precursor-like protein, Amyloid βeta precursor protein, Spinocerebellar ataxia gene, Synapsin 1, Endothelin receptor, S100 (callizzarin), Nieman-Pick type C2. |
1. The genes listed include the top 1% of all transcripts with present calls, plus selected genes from the next 5% of the most abundant transcripts observed in all 15 arrays. The selected genes were chosen based on their previous documentation as hematopoietic/macrophage/immune cell markers and/or association with the CNS or neurodegenerative disease. For a complete list of gene transcript expression levels, probe sets, and genebank accession numbers please refer to supplemental information found at EMBL-EBI, accession E-MEXP-459 and in the additional file accompanying this paper.
Figure 3Microglial gene array analysis shows no global changes resulting from NN or NV ecotropic MLV infection. Affymetrix 430A chips were used to assess global changes associated with infecting primary microglial cells with either Fr57E or FrCasE. Present/Absent calls were based on analysis using Microarray Suite 5.0 from Affymetrix. Aqua bars = Totals for all microglial arrays (n = 15); black = FrCasE-infected (n = 5); gray = Fr57E-infected (n = 5); white = Mock-infected.
Figure 4Transcriptional profile comparison between mock-, Fr57E- and FrCasE-infected microglia identifies a very small number of differentially expressed genes. Average normalized expression levels for the genes and ESTs represented on the Affymetrix 430A mouse chip were compared for each condition and plotted as pairwise comparisons. Panel A shows comparisons between MLV – infected and mock-infected control microglia. Note that very few genes with normalized intensity values >100 were found off the diagonal (which represents equal expression). Panel B shows a comparison between microglia infected with the non-neurovirulent virus Fr57E and the highly neurovirulent virus FrCasE. The identification of a few differentially expressed genes (circled) is provided. A complete listing of the differentially expressed genes is provided in tables 2-4.
Differentially Expressed Genes between Mock- and Fr57E Non-neurovirulent Virus-infected Microglia
| Callb | ||||||||||
| 1425923_at | *neuroblastoma myc-related oncogene 1 | M36277 | Transcription/cell cycle control | 6.96 | 27.32 | A | 2189.17 | 113.3 | P | 314.68 |
| 1425131_at | *protein tyrosine phosphatase, non-receptor type 5 | U28216 | Tyrosine phosphatase | -101.71 | 12.11 | A | 220.58 | 45.16 | A | 220.58 |
| 1456182_x_at | *melanoma antigen (env polyprotein) | BB795191 | retroviral envelope protein | 39.08 | 9.27 | A | 1057.46 | 164.85 | A | 27.06 |
| 1427694_at | *gonadotropin releasing hormone receptor | L28756 | G-protein coupled receptor | 26.1 | 6.83 | A | 236.32 | 27.04 | A | 9.05 |
| 1429212_a_at | *RIKEN cDNA 1700008D07 gene (testis cDNA) | AK005758 | Inflammatory response | 27.15 | 6.67 | A | 200.55 | 23.75 | A | 7.39 |
| 1422720_at | *ISL1 transcription factor, LIM/homeodomain, (islet-1) | NM_021459 | Transcription factor/development | 28.05 | 13.62 | A | 204.31 | 17.73 | A | 7.28 |
| 1431213_a_at | *RIKEN cDNA 1300007C21 gene (vaginal cDNA) | BG297038 | Retrovirus-related POL polyprotein | 43.54 | 12.85 | P | 234.29 | 93.25 | P | 5.38 |
| 1455788_x_at | *Polymerase (DNA-directed), delta interacting protein 3 | BB495487 | Nucleic acid binding | 168.36 | 116.73 | P | 832.13 | 40.86 | P | 4.94 |
| 1452288_at | *expressed sequence BB128963 (neonatal cerebellum) | BG071933 | Similar to myotubularin related proteins | 64.79 | 36.28 | mA | 284.96 | 32.16 | mA | 4.4 |
| 1450824_at | *patched homolog | NM_008957 | Hedgehog receptor | 82.11 | 17.51 | A | 237.39 | 24.44 | A | 2.89 |
| 1450610_at | *urocortin | NM_021290 | Neuropeptide signaling | 66.48 | 25.27 | A | 185.56 | 23.69 | A | 2.79 |
| 1424887_at | BC012312 | No annotation | 107.6 | 19.51 | mA | 254.85 | 59.56 | mA | 2.37 | |
| 1460469_at | *tumor necrosis factor receptor superfamily, member 9 | BM250782 | Receptor/defense response | 148.29 | 28.95 | A | 311.04 | 32.32 | mA | 2.1 |
| 1451107_at | *TBC1 domain family, member 22a | BC023106 | GTPase activator activity | 296.8 | 27.95 | mA | 610.17 | 47.13 | mA | 2.06 |
| 1449036_at | # | AK004847 | (-) regulation of cytokine synthesis | 180.46 | 26.71 | P | 292.69 | 27.22 | P | 1.62 |
*Genes with asterisks showed differential expression in both Fr57E- and FrCasE-infected microglia when compared to mock-infected microglia (see table 3).
Bolded genes are those that show differential expression only in Fr57E-infected microglia compared to mock-infected microglia.
# This gene was included based on statistical differences (p < 0.05) and its potential immune modulatory function, despite falling below the arbitrary two-fold cut off threshold.
a- Function/process was determined by gene ontology information provided through the Affymetrix NetAffx Analysis Center and its links to PubMed, EMBL, etc.
b-A = Absent call in 5/5 arrays; mA = Absent calls in 3–4/5 arrays; P = Present call in 5/5 arrays; mP = present calls in 3–4/5 arrays
Differentially Expressed Genes Between Mock- and FrCasE-infected Microglia
| probe set | gene | Accession | Function/processa | mean | SE | Callb | mean | SE | Callb | fold change |
| 1425923_at | *neuroblastoma myc-related oncogene 1 | M36277 | Transcription/cell cycle control | 6.96 | 27.32 | A | 2239.4 | 116.8 | mP | 321.9 |
| 1425131_at | *protein tyrosine phosphatase, non-receptor type 5 | U28216 | Tyrosine phosphatase | -101.71 | 12.11 | A | 235.6 | 48.34 | A | 235.6 |
| 1431214_at | *RIKEN cDNA 1300007C21 gene (vaginal cDNA) | BG297038 | Retrovirus-related POL polyprotein | -14.82 | 11.41 | A | 146.69 | 79.6 | mP | 146.69 |
| 1456182_x_at | *melanoma antigen | BB795191 | Viral envelope related | 39.08 | 9.27 | A | 939.13 | 74.66 | A | 24.03 |
| 1431213_a_at | *RIKEN cDNA 1300007C21 gene(vaginal cDNA) | BG297038 | Retrovirus-related POL polyprotein | 43.54 | 12.85 | P | 571.78 | 257.8 | P | 13.13 |
| 1427694_at | *gonadotropin releasing hormone receptor | L28756 | G-protein coupled receptor | 26.1 | 6.83 | A | 218.05 | 14.59 | A | 8.35 |
| 1422720_at | *ISL1 transcription factor, LIM/homeodomain, (islet-1) | NM_021459 | Transcription factor/development | 28.05 | 13.62 | A | 215.44 | 14.84 | A | 7.68 |
| 1429212_a_at | *RIKEN cDNA 1700008D07 gene (testis cDNA) | AK005758 | Inflammatory response | 27.15 | 6.67 | A | 187.81 | 39.86 | A | 6.92 |
| 1455788_x_at | *Polymerase (DNA-directed), delta interacting protein 3 | BB495487 | Nucleic acid binding | 168.36 | 116.7 | P | 919.68 | 61.16 | P | 5.46 |
| 1452288_at | *expressed sequence BB128963 (neonatal cerebellum) | BG071933 | Similar to myotubularin related proteins | 64.79 | 36.28 | mA | 352.56 | 23.76 | mA | 5.44 |
| 1449163_at | NM_023059 | Immune reponse inhibition | 75.17 | 22.22 | mA | 405.05 | 69.42 | mP | 5.39 | |
| 1425260_at | BC024643 | Carrier protein | 32.31 | 11.17 | A | 136.36 | 15.27 | A | 4.22 | |
| 1450610_at | *urocortin | NM_021290 | Neuropeptide signaling | 66.48 | 25.27 | A | 208.42 | 18.38 | A | 3.13 |
| 1450824_at | *patched homolog | NM_008957 | Hedgehog receptor | 82.11 | 17.51 | A | 245.79 | 33.45 | A | 2.99 |
| 1437712_x_at | AV212315 | exonuclease/RNA processing | 347.13 | 128.5 | A | 988.22 | 288.1 | A | 2.85 | |
| 1451107_at | *TBC1 domain family, member 22a | BC023106 | GTPase activator | 296.8 | 27.95 | mA | 605.2 | 52.13 | mA | 2.04 |
| 1460469_at | *tumor necrosis factor receptor superfamily, member 9 | BM250782 | Receptor/defense response | 148.29 | 28.95 | A | 297.71 | 36.4 | mA | 2.01 |
| 1451382_at | BC025169 | ChaC, cation transport regulator-like | 209.65 | 14.12 | mP | 35.33 | 54.81 | mA | -5.93 | |
*Genes with asterisks are those that showed differential expression in both Fr57E- and FrCasE-infected microglia when compared to mock-infected microglia (see table 2).
genes are those that show differential expression only in FrCasE-infected microglia compared to mock-infected microglia.
a- Function/process was determined by gene ontology information provided through the Affymetrix NetAffx Analysis Center and its links to PubMed, EMBL, etc.
b-A = Absent call in 5/5 arrays; mA = Absent calls in 3–4/5 arrays; P = Present call in 5/5 arrays; mP = present calls in 3–4/5 arrays. Call determined by Microarray suite 5.0 (Affymetrix) SE-Standard Error.
Differentially Expressed Genes Between Fr57E- and FrCasE-infected Microglia
| 1449163_at | NM_023059 | Immune reponse inhibition | 72.42 | 28.86 | mA | 405.05 | 69.42 | mP | 5.39 | |
| 1437712_x_at | AV212315 | exonuclease/RNA processing | 352.67 | 101 | A | 988.22 | 288.1 | A | 2.8 | |
| 1451382_at | BC025169 | ChaC, cation transport regulator-like | 186.12 | 19.03 | mP | 35.33 | 54.81 | mA | -5.27 | |
genes are those that show differential expression in FrCasE-infected microglia when compared to mock- and Fr57E-infected microglia.
a-Function/process was determined by gene ontology information provided through the Affymetrix NetAffx Analysis Center and its links to PubMed, EMBL, etc.
b-A = Absent call in 5/5 arrays; mA = Absent calls in 3–4/5 arrays; P = Present call in 5/5 arrays; mP = present calls in 3–4/5 arrays
Figure 5Taqman real-time RT-PCR validation assessment of microglial genes identified in Fr57E versus FrCasE gene arrays. Panel A shows qRT-PCR analysis of RNA from two independent microglial culture experiments assaying three separate cultures in triplicate for SIGIRR, exosome component 4 (Exosc4), and Riken cDNA 1810008K03 gene (ChaC). These cultures were distinct from those used for microarray analysis. Panel B shows qRT-PCR analysis of SIGIRR RNA obtained from microglia isolated from the brains of virus-infected and uninfected mice. FrCasE- infected (black); F43- infected (gray); mock-infected (white)